Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H30N2O4S2 |
Molecular Weight | 438.604 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)S(=O)(=O)NC[C@H](C)C1=CC=C(C=C1)C2=CC=C(CCNS(C)(=O)=O)C=C2
InChI
InChIKey=ULRDYYKSPCRXAJ-KRWDZBQOSA-N
InChI=1S/C21H30N2O4S2/c1-16(2)29(26,27)23-15-17(3)19-9-11-21(12-10-19)20-7-5-18(6-8-20)13-14-22-28(4,24)25/h5-12,16-17,22-23H,13-15H2,1-4H3/t17-/m0/s1
Molecular Formula | C21H30N2O4S2 |
Molecular Weight | 438.604 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/23257314Curator's Comment: description was created based on several sources, including
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23257314
Curator's Comment: description was created based on several sources, including
Mibampator, also known as LY451395, is a potent and highly selective an AMPA receptor potentiator, which plays a role in the regulation of the glutamatergic system. The AMPA system also has important functions in the regulation of synapses, synaptic regeneration, and neuroprotection and is therefore a good therapeutic target for treatments aiming to improve cognition and function or alter disease progression. Mibampator was in the phase II clinical trial for the treatment of agitation and aggression in Alzheimer's disease (AD).
CNS Activity
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23257314
Curator's Comment: # Lilly Research Laboratories, Eli Lilly and Company
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2096670 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16554450 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.082 ng/mL |
5 μg single, oral dose: 5 μg route of administration: Oral experiment type: SINGLE co-administered: |
MIBAMPATOR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
219 ng/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
MIBAMPATOR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8.39 h |
5 μg single, oral dose: 5 μg route of administration: Oral experiment type: SINGLE co-administered: |
MIBAMPATOR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
11.8 h |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
MIBAMPATOR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease. | 2013 May |
|
Randomized controlled trial of mibampator for behavioral and psychological symptoms of dementia: comments on the trial and thoughts for future studies. | 2013 May |
|
Randomized controlled trial of mibampator for behavioral and psychological symptoms of dementia: comments on the trial and thoughts for future studies - ADDENDUM. | 2014 Jul 3 |
|
Progresses in treating agitation: a major clinical challenge in Alzheimer's disease. | 2015 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00843518
3 mg BID oral 12 weeks. May be reduced to 1 mg if unable to tolerate
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:14:54 GMT 2023
by
admin
on
Fri Dec 15 18:14:54 GMT 2023
|
Record UNII |
A9V5BW73UU
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
300000034286
Created by
admin on Fri Dec 15 18:14:54 GMT 2023 , Edited by admin on Fri Dec 15 18:14:54 GMT 2023
|
PRIMARY | |||
|
A9V5BW73UU
Created by
admin on Fri Dec 15 18:14:54 GMT 2023 , Edited by admin on Fri Dec 15 18:14:54 GMT 2023
|
PRIMARY | |||
|
Mibampator
Created by
admin on Fri Dec 15 18:14:54 GMT 2023 , Edited by admin on Fri Dec 15 18:14:54 GMT 2023
|
PRIMARY | |||
|
375345-95-2
Created by
admin on Fri Dec 15 18:14:54 GMT 2023 , Edited by admin on Fri Dec 15 18:14:54 GMT 2023
|
PRIMARY | |||
|
WW-70
Created by
admin on Fri Dec 15 18:14:54 GMT 2023 , Edited by admin on Fri Dec 15 18:14:54 GMT 2023
|
PRIMARY | |||
|
C174617
Created by
admin on Fri Dec 15 18:14:54 GMT 2023 , Edited by admin on Fri Dec 15 18:14:54 GMT 2023
|
PRIMARY | |||
|
DB12717
Created by
admin on Fri Dec 15 18:14:54 GMT 2023 , Edited by admin on Fri Dec 15 18:14:54 GMT 2023
|
PRIMARY | |||
|
9260
Created by
admin on Fri Dec 15 18:14:54 GMT 2023 , Edited by admin on Fri Dec 15 18:14:54 GMT 2023
|
PRIMARY | |||
|
DTXSID20190977
Created by
admin on Fri Dec 15 18:14:54 GMT 2023 , Edited by admin on Fri Dec 15 18:14:54 GMT 2023
|
PRIMARY | |||
|
CHEMBL1277001
Created by
admin on Fri Dec 15 18:14:54 GMT 2023 , Edited by admin on Fri Dec 15 18:14:54 GMT 2023
|
PRIMARY | |||
|
9889366
Created by
admin on Fri Dec 15 18:14:54 GMT 2023 , Edited by admin on Fri Dec 15 18:14:54 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET->POSITIVE ALLOSTERIC MODULATOR (PAM) |
High-impact AMPAR PAM decreases both deactivation and desensitization together to enhance and prolong synaptic currents.
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |